2017
Outcomes from Autologous Hematopoietic Cell Transplantation versus Chemotherapy Alone for the Management of Light Chain Amyloidosis
Oke O, Sethi T, Goodman S, Phillips S, Decker I, Rubinstein S, Concepcion B, Horst S, Jagasia M, Kassim A, Harrell SL, Langone A, Lenihan D, Rawling KT, Slosky D, Cornell RF. Outcomes from Autologous Hematopoietic Cell Transplantation versus Chemotherapy Alone for the Management of Light Chain Amyloidosis. Transplantation And Cellular Therapy 2017, 23: 1473-1477. PMID: 28546074, DOI: 10.1016/j.bbmt.2017.05.020.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAntineoplastic AgentsBortezomibFemaleHematopoietic Stem Cell TransplantationHumansImmunoglobulin Light-chain AmyloidosisInduction ChemotherapyMaleMiddle AgedMultivariate AnalysisNatriuretic Peptide, BrainProportional Hazards ModelsProteinuriaRetrospective StudiesStroke VolumeTransplantation, AutologousTreatment OutcomeConceptsAutologous hematopoietic cell transplantationProgression-free survivalTransplantation-related mortalityHematopoietic cell transplantationOverall survivalCT cohortLight chain amyloidosisCell transplantationLower brain natriuretic peptide levelsChain amyloidosisBrain natriuretic peptide levelsMedian progression-free survivalSuperior progression-free survivalBortezomib-based treatmentExperienced transplantation centersGood partial responseNatriuretic peptide levelsCohort of patientsMajority of patientsHigher ejection fractionEligible patientsInduction chemotherapyInduction therapyPartial responseEjection fraction
2016
A Comprehensive Assessment of Toxicities in Patients with Central Nervous System Lymphoma Undergoing Autologous Stem Cell Transplantation Using Thiotepa, Busulfan, and Cyclophosphamide Conditioning
Scordo M, Bhatt V, Hsu M, Omuro AM, Matasar MJ, DeAngelis LM, Dahi PB, Moskowitz CH, Giralt SA, Sauter CS. A Comprehensive Assessment of Toxicities in Patients with Central Nervous System Lymphoma Undergoing Autologous Stem Cell Transplantation Using Thiotepa, Busulfan, and Cyclophosphamide Conditioning. Transplantation And Cellular Therapy 2016, 23: 38-43. PMID: 27713090, PMCID: PMC5518313, DOI: 10.1016/j.bbmt.2016.09.024.Peer-Reviewed Original ResearchConceptsAutologous stem cell transplantationPrimary central nervous system lymphomaSecondary central nervous system lymphomaCentral nervous system lymphomaProgression-free survivalNervous system lymphomaTransplantation-related mortalityStem cell transplantationOverall survivalSystem lymphomaCyclophosphamide conditioningNonhematologic toxicityCell transplantationTreatment strategiesTime of ASCTFavorable progression-free survivalHigh-dose therapyBusulfan areaBusulfan dosingAdult patientsPatient characteristicsMedian numberToxicity burdenPatientsConsiderable toxicity
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply